TrialAntimicrobial agents and chemotherapy2009

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

James F Demarest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.